このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Aurinia Pharmaceuticals 将来の成長
Future 基準チェック /46
Aurinia Pharmaceuticalsは、52%と18.2%でそれぞれ年率52%で利益と収益が成長すると予測される一方、EPSはgrowで52%年率。
主要情報
52.0%
収益成長率
52.0%
EPS成長率
| Biotechs 収益成長 | 24.2% |
| 収益成長率 | 18.2% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 03 May 2024 |
今後の成長に関する最新情報
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Recent updates
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Aurinia Pharmaceuticals: The Right Play Now
Aug 24Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
Aug 15Aurinia Pharma Q2 2022 Earnings Preview
Aug 03Aurinia lupus nephritis drug recommended in Europe
Jul 22A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
Jul 04業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | 350 | 133 | 74 | N/A | 4 |
| 12/31/2025 | 282 | 71 | 41 | 69 | 7 |
| 12/31/2024 | 227 | 9 | N/A | 3 | 7 |
| 3/31/2024 | 191 | -63 | -21 | -20 | N/A |
| 12/31/2023 | 176 | -78 | -34 | -33 | N/A |
| 9/30/2023 | 159 | -77 | -38 | -37 | N/A |
| 6/30/2023 | 160 | -73 | -40 | -39 | N/A |
| 3/31/2023 | 147 | -97 | -65 | -64 | N/A |
| 12/31/2022 | 134 | -108 | -80 | -80 | N/A |
| 9/30/2022 | 129 | -115 | -110 | -116 | N/A |
| 6/30/2022 | 88 | -157 | -141 | -141 | N/A |
| 3/31/2022 | 66 | -168 | -151 | -151 | N/A |
| 12/31/2021 | 46 | -181 | -159 | -158 | N/A |
| 9/30/2021 | 72 | -156 | -138 | -129 | N/A |
| 6/30/2021 | 58 | -148 | -125 | -117 | N/A |
| 3/31/2021 | 51 | -127 | -109 | -101 | N/A |
| 12/31/2020 | 50 | -103 | -77 | -70 | N/A |
| 9/30/2020 | 0 | -129 | -104 | -98 | N/A |
| 6/30/2020 | 0 | -110 | -83 | -82 | N/A |
| 3/31/2020 | 0 | -102 | -73 | -73 | N/A |
| 12/31/2019 | 0 | -88 | -64 | -64 | N/A |
| 9/30/2019 | 0 | -57 | -52 | -52 | N/A |
| 6/30/2019 | 0 | -52 | -51 | -51 | N/A |
| 3/31/2019 | 0 | -61 | -50 | -50 | N/A |
| 12/31/2018 | 0 | -53 | -52 | -52 | N/A |
| 9/30/2018 | 0 | -53 | -47 | -47 | N/A |
| 6/30/2018 | 0 | -48 | -44 | -44 | N/A |
| 3/31/2018 | 0 | -34 | -46 | -46 | N/A |
| 12/31/2017 | 0 | -71 | N/A | -41 | N/A |
| 9/30/2017 | 0 | -76 | N/A | -36 | N/A |
| 6/30/2017 | 0 | -70 | N/A | -32 | N/A |
| 3/31/2017 | 0 | -71 | N/A | -23 | N/A |
| 12/31/2016 | 0 | -23 | N/A | -19 | N/A |
| 9/30/2016 | 0 | -19 | N/A | -19 | N/A |
| 6/30/2016 | 0 | -17 | N/A | -20 | N/A |
| 3/31/2016 | 0 | -14 | N/A | -19 | N/A |
| 12/31/2015 | 0 | -19 | N/A | -18 | N/A |
| 9/30/2015 | 0 | -21 | N/A | -16 | N/A |
| 6/30/2015 | 0 | -13 | N/A | -15 | N/A |
| 3/31/2015 | 0 | -23 | N/A | -16 | N/A |
| 12/31/2014 | 0 | -19 | N/A | -17 | N/A |
| 9/30/2014 | 1 | -15 | N/A | -16 | N/A |
| 6/30/2014 | 1 | -17 | N/A | -14 | N/A |
| 3/31/2014 | 1 | -7 | N/A | -10 | N/A |
| 12/31/2013 | 1 | -3 | N/A | -5 | N/A |
| 9/30/2013 | 0 | -6 | N/A | -3 | N/A |
| 6/30/2013 | 0 | -8 | N/A | -2 | N/A |
アナリストに よる今後の成長予測
収入対貯蓄率: AUPHは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。
収益対市場: AUPH今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: AUPH今後 3 年以内に収益を上げることが予想されます。
収益対市場: AUPHの収益 ( 18.2% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: AUPHの収益 ( 18.2% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: AUPHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です